Promising results have been demonstrated with ErbB2/HER2-specific NK cells in preclinical models of GBM, where they were shown to selectively target and kill glioblastoma cells both in vivo and in vitro (Zhang et al., 2016; Hosseinalizadeh et al., 2022). Here, ERBB2 is linked to glioblastoma.